Biological Therapies for Cancer

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Volumn , Issue , 2013, Pages 303-342

  Price, Karen D ^a   Rao, Gautham K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Immunotherapy; Oncology biologic; Toxicology

Indexed keywords

EID: 84903807153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394810-6.00013-7     Document Type: Chapter

References (108)

1. Baxevanis C.N., Perez S.A., Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009, 58:317-324.
2. Boyle R.M. The use of biologics in cancer therapy. US Pharm 2010, 35(3):4-7. Oncology suppl.
3. Chiriva-Internati M., Grizzi F., Wachtel M.S., et al. Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci 2008, 53:836-843.
4. Brennan and Bria E., Cuppone F., Milella M., Verma S., Carlini P., Nistico C., et al. Trastuzumab cardiotoxicity: Biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008, 8:1963-1971.
5. ICH ICH Topic M3. Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals 1997, Current Step 4 version Dated July 1997.
6. ICH Topic S6. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Current Step 4 version Dated July 1997.
7. ICH Harmonized Tripartite Guideline. Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, S6(R1). Current Step 2 version Dated October 29, 2009.
8. ICH Topic S9. Nonclinical Evaluation for Anticancer Pharmaceuticals. Current Step 4 version Dated March 2010.
9. Wang T., Jacobson-Kram D., Pilaro A.M., Lapadula D., Jacobs A., Brown P., et al. ICH Guidances: Inception, revision, and implementation for drug development. Tox Sci 2010, 118(2):356-357.
10. O'Conner A. Introduction to biotech drugs. Reg Rapport 2009, 6(1):4-7.
11. Tibbitts J., Cavagnaro J.A., Haller C.A., Marafino B., Andrews P.A., Sullivan J.T. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Reg Tox Pharmacol 2010, 58:243-251.
12. Bussiere J. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin Drug Metab Toxicol 2008, 4(7):871-877.
13. Bugelski P.J., Herzyk D.J., Rehm S., Harmsen A.G., Gore E.V., Williams D.M., et al. Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: Characterization of the model and safety studies. Hum Exp Toxicol 2000, 19(4):230-243.
14. Tabrizi M.A., Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Disc Today 2007, 12(13-14):540-547.
15. Baumann A. Preclinical development of therapeutic biologics. Expert Opin Drug Discov 2008, 8(3):289-297.
16. DeGeorge J.J., Ahn C.-H., Andrews P.A., Brower M.E., Giorgio D.W., Goheer M.A., et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998, 41:173-185.
17. Haller C.A., Cosenza M.E., Sullivan J.T. Safety issues specific to clinical development of protein therapeutics. Clin Pharmacol Therap 2008, 84(5):624-627.
18. Prueksaritanont T., Tang C. ADME of biologics-what have we learned from small molecules?. AAPS J 2012, 14(3):410-419.
19. Weinbauer G.F., Fuchs A., Niehaus M., Luetjens C.M. The enhanced pre- and postnatal study for nonhuman primates: Update and perspectives. Birth Defects Res C Embryo Today 2011, 93(4):324-333.
20. ICH Topic S1a. Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals. Current Step 4 version Dated Nov 1995.
21. Chen C., Constantinou A., Chester K.A., Vyas B., Canis K., Haslam S.M., et al. Glycoengineering approach to half-life extension of recombinant biotherapeutics. Bioconjug Chem 2012, 23(8):1524-1533.
22. Xu X., Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J 2012, 14(4):781-791.
23. Xin Y., Bai S., Damico-Beyer L.A., Jin D., Liang W.-C., Wu Y., et al. Anti-neuropilin-1 (MNRP1685A): Unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharmac Res 2012, 29(9):2512-2521.
24. Bumbaca D., Wong A., Drake E., Reyes A.E., Lin B.C., Stephan J.P., et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011, 3(4):376-386.
25. Caravella J., Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010, 14:520-528.
26. Stubenrauch K., Wessels U., Essig U., Vogel R., Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J Pharmaceut Biomed Analysis 2010, 52(2):249-254.
27. Maitland M.L., Schilsky R.L. Clinical trials in the era of personalized oncology. Cancer J Clin 2011, 61(6):365-381.
28. Kummar S., Gutierrez M., Doroshow J.H., Murgo A.J. Drug development in oncology: Classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006, 62(1):15-26.
29. Floyd E., McShane T.M. Development and use of biomarkers in oncology drug development. Toxic Path 2004, 32(1):106-115.
30. Hodgson D.R., Whittaker R.D., Herath A., Amakye D., Clack G. Biomarkers in oncology drug development. Mol Oncol 2009, 3:24-32.
31. Waterton J.C., Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 2012, 48:409-415.
32. Schuster M., Nechansky A., Kircheis R. Cancer immunotherapy. Biotechnol J 2006, 1:138-147.
33. Gregory S.A., Hohloch K., Gisselbrecht C., et al. Harnessing the energy: Development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Oncologist 2009, 14(Suppl. 2):4-16.
34. Sharkey R.M., Goldenberg D.M. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56:226-243.
35. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007, 26:3603-3613.
36. Fleischmann R.M. Safety of biologic therapy in rheumatoidarthritis and other autoimmune diseases: Focus on rituximab. Semin Arthritis Rheum 2009, 38:265-280.
37. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
38. Ram R., Ben-Bassat I., Shpilberg O., Polliack A., Raanani P. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma 2009, 50:1083-1095.
39. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mousehuman monoclonal antibody to CD20. Blood 1994, 83:435-445.
40. Goldenberg D.M., Morschhauser F., Wegener W.A. Veltuzumab (humanized anti-CD20 monoclonal antibody): Characterization, current clinical results, and future prospects. Leuk Lymphoma 2010, 51:747-755.
41. Gaufin T., Pattison M., Gautam R., Stoulig C., Dufour J., MacFarland J., et al. Effect of B-cell depletion on viral replication andclinical outcome of simian immunodeficiency virus infection in anatural host. J Virol 2009, 83:10347-10357.
42. Bugelski P.J., Martin P.L. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: Cell surface targets. Br J Pharmacol 2012, 166:823-846.
43. European Medicines Agency Scientific Discussion on Rituximab http://www.ema.europa.eu/%20docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf.
44. Vaidyanathan A., McKeever K., Anand B., Eppler S., Weinbauer G.F., Beyer J.C. Developmental immunotoxicology assessment ofrituximab in cynomolgus monkeys. Toxicol Sci 2011, 119:116-125.
45. Rituxan USPI http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf.
46. European Medicines Agency Scientific Discussion on Avastin http://www.ema.europa.eu/%20docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000582/WC500029262.pdf.
47. Kim K.J., Li B., Houck K., Winer J., Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7(1):53-64.
48. Ferrara N., Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106(4):148-156.
49. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
50. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380(6573):439-442.
51. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380(6573):435-439.
52. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18(1):4-25.
53. Matsumoto T., Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001, 2001(112):RE21.
54. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996, 93(25):14765-14770.
55. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273(21):13313-13316. 1998.
56. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273(46):30336-30343.
57. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established humantumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103(2):159-165.
58. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation incoronary arteries. Am J Physiol 1993, 265(2 Pt 2):H586-H592.
59. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146(5):1029-1039.
60. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219(4587):983-985.
61. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990, 172(6):1535-1545.
62. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumorsinhibits the functional maturation of dendritic cells. Nat Med 1996, 2(10):1096-1103.
63. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57(20):4593-4599.
64. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362(6423):841-844.
65. Borgstrom P., Hillan K.J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996, 56(17):4032-4039.
66. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovariancancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153(4):1249-1256.
67. Borgstrom P., Bourdon M.A., Hillan K.J., Sriramarao P., Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35(1):1-10.
68. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95(4):1789-1797.
69. Soffer S.Z., Moore J.T., Kim E., Huang J., Yokoi A., Manley C., et al. Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001, 36(8):1177-1181.
70. McCrudden K.W., Hopkins B., Frischer J., Novikov A., Huang J., Kadenhe A., et al. Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003, 38(3):308-314.
71. Sweeney C.J., Miller K.D., Sissons S.E., Nozaki S., Heilman D.K., Shen J., et al. The antiangiogenic property of docetaxel is synergistic with arecombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61(8):3369-3372.
72. Hotz H.G., Hines O.J., Hotz B., Foitzik T., Buhr H.J., Reber H.A. Evaluation of vascular endothelial growth factor blockade and matrixmetalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg 2003, 7(2):220-227. discussion 227-8.
73. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000, 60(19):5565-5570.
74. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002, 161(5):1917-1924.
75. Kim E.S., Soffer S.Z., Huang J., McCrudden K.W., Yokoi A., Manley C.A., et al. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg 2002, 37(3):518-522.
76. Shima D.T., Gougos A., Miller J.W., Tolentino M., Robinson G., Adamis A.P., et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996, 37(7):1334-1340.
77. Ryan A.M., Eppler D.B., Hagler K.E., Bruner R.H., Thomford P.J., Hall R.L., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999, 27(1):78-86.
78. Howdieshell T.R., Riegner C., Gupta V., Callaway D., Grembowicz K., Sathyanarayana, et al. Normoxic wound fluid contains high levels of vascular endothelial growth factor. Ann Surg 1998, 228(5):707-715.
79. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L., DiPietro L.A. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998, 152(6):1445-1452.
80. Tonnesen M.G., Feng X., Clark R.A. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000, 5(1):40-46.
81. Health Canada Product monograph for Herceptin http://rochecanada.com/fmfiles/%20re7234008/%20Research/ClinicalTrialsForms/Products/ConsumerInformation/Monographsand%20PublicAdvisories/Herceptin/herceptinSept14SIE.pdf.
82. Lee K.S. Requirement for neuroregulin receptor, erbB2, in neural and cardiac development. Nature 1995, 379:394-396.
83. Carter P., Presta L., Gorman C.M., Ridgway J.B.B., Henner D., Wong W.L.T., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
84. European Medicines Agency Scientific Discussion on Herceptin http://www.ema.europa.eu/%20docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000278/WC500049816.pdf.
85. Fanale M.A., Uyei A.R., Theriault R.L., Adam K., Thompson R.A. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 2005, 6(4):354-356.
86. European Medicines Agency Assessment Report for Ipilimumab http://www.ema.europa.eu/%20docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002213/WC500109302.pdf.
87. US Food and Drug Administration Yervoy Prescribing INformation (Yervoy Label) http://www.accessdata.fda.gov/%20drugsatfda_docs/label/2011/125377s00001bl.pdf.
88. Chambers C.A., Sullivan T.J., Allison J.P. Lymphoproliferation in CTLA-4deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997, 7(6):885-895.
89. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
90. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270(5238):985-988.
91. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3(7):611-618.
92. Misbah S.A., Chapel H.E. Adverse effects of intravenous immunoglobulin. Drug Safety 1993, 9(4):254-262.
93. Soetens F.M. Anaphylaxis during anaesthesia:diagnosis and treatment. Acta Anaesthesiol Belg 2004, 55(4):229-237.
94. Mertes P.M., Laxenaire M.C. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002, 19(4):240-262.
95. Yoshizawa K., Oishi Y., Matsumoto M., Nyska A. Ischemic brain damage after ketamine and xylazine treatment in a young laboratory monkey (Macaca fascicularis). Contemp Top Lab Anim Sci 2005, 44(5):19-24.
96. Ochsner A.J. Cardiovascular and respiratory responses to ketamine hydrochloride in the rhesus monkey (Macaca mulatta). Lab Anim Sci 1977, 27(1):69-71.
97. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54(12):3782-3789.
98. Mayer L., Young Y. Infusion reactions and their management. Gastroenterol Clin N Am 2006, 35:857-866.
99. Aguilar Rebolledo F. Interferons in neurology. Rev Invest Clin 2000, 52:665-679.
100. Trown P.W., Wills R.J., Kamm J.J. The preclinical development of Roferon-A. Cancer 1986, 57:1648-1656.
101. Roferon-A Prescribing Information (Roferon-A Label) http://dailymed.nlm.nih.gov/dailymed%20/drugInfo.cfm%3Fid%3D8326.
102. Isaacs A., Lindenmann J. Virus interference: I. The interferon. Proc R Soc Lond [B] 1957, 147:258-267.
103. Kramer M.J., Dennin R., Kramer C., et al. Cell and virus sensitivitystudies with recombinant human alpha interferons. J Interferon Res 1983, 41:1-416.
104. Weck P.K., Apperson S., May L., Stebbing N. Comparison of the antiviral activities of various cloned human interferon-a subtypes in mammalian cell cultures. J Gen Virol 1981, 57:233-237.
105. Stebbing N., Weck P.K., Fenno J.T., Estell D.A., Rinderknecht E. Antiviral effects of bacteria-derived human leukocyte interferon against encephalomyocarditisvirus infection of squirrel monkeys. Arch Virol 1983, 76(4):365-367.
106. Soike K.F., Kramer M.J., Gerone P.J. In vivo antiviral activity of recombinant type a interferon A in monkeys with infections due to simian varicella virus. J Infect Dis 1983, 147:933-938.
107. Kern E.R., Richards J.T., Overall J.C., Kramer M.J., Trown P.W. Effective treatment of a genital herpes simplex virus type 2 infection ofguinea pigs with recombinant human leukocyte A interferon. Proc 13th Int Cong Chemother 1983, 6:60/31-60/34.
108. Vijayalaxmi Human leukocyte interferon does not induce sister-chromatid exchanges in human blood lymphocytes. Mutat Res 1982, 105:287-290.